ÇAĞMAN TAN, RIZA KÖKSAL ÖZGÜL, DENİZ NAZİRE ÇAĞDAŞ AYVAZ, İlhan TEZCAN, Özden SANAL

Polymorphisms in FAS and CASP8 genes may contribute to the development of ALPS phenotype: a study in 25 patients with probable ALPS

Defects in genes that have role in apoptotic pathways result in development of Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS related disorders. Germline and somatic FAS mutations, FASL and CASP10 mutations constitute other genetic defects in ALPS. Patients who fulfill ALPS diagnostic criteria and do not have any identified known disease causing mutations are classified as ALPS-unknown or ALPS phenotype and comprise about one third of all patients. CASP8, NRAS and KRAS gene mutations were reported for ALPS related diseases. We performed DNA sequence analysis in 25 unrelated patients with probable ALPS for FAS, FASL and CASP8 gene defects. Pathogenic mutations could not be found in the FAS, FASL and CASP8 genes. However, we found that the frequencies of SNPs rs2234978 and rs1045487 of FAS and CASP8 genes were significantly higher in the patients. Our results suggest that CASP8 and FAS gene polymorphisms in particular, may contribute to the susceptibility to development of ALPS phenotype.

PDF

___

1. Lenardo M, Chan KM, Hornung F, et al. Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999; 17: 221-253.

2. Su HC, Lenardo MJ. Genetic defects of apoptosis and primary immunodeficiency. Immunol Allergy Clin North Am 2008; 28: 329-351, ix.

3. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 2010;116: 35-40.

4. Magerus-Chatinet A, Stolzenberg MC, Lanzarotti N. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation. J Allergy Clin Immunol 2013;131: 486-490.

5. Fleisher TA,Oliveira JB. Monogenic defects in lymphocyte apoptosis. Curr Opin Allergy Clin Immunol 2012; 12: 609-615.

6. Brookes AJ. The essence of SNPs. Gene 1999;234: 177-186.

7. Pu X, Roth JA, Hildebrandt MA, et al. MicroRNArelated genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients. Cancer Res 2013; 73: 1867-1875.

8. Glavan BJ, Holden TD, Goss CH, et al. Genetic variation in the FAS gene and associations with acute lung injury. Am J Respir Crit Care Med 2011;183: 356-363.

9. Huang QR, Danis V, Lassere M, et al. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 1999; 38: 645-651.

10. Kanemitsu S, Ihara K, Saifddin A, et al. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002; 29: 1183-1188.

11. Kantarci OH, Hebrink DD, Achenbach SJ, et al. CD95 polymorphisms are associated with susceptibility to MS in women. A population-based study of CD95 and CD95L in MS. J Neuroimmunol 2004; 146: 162-170.

12. Bleesing JJ, Brown MR, Straus SE, et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood 2001; 98: 2466-2473.

13.Teachey DT, New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr 2012; 24: 1-8.

14. Clementi R, Chiocchetti A, Cappellano G, et al. Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas function. Blood 2006;108: 3079-3084.

15. Cerutti E, Campagnoli MF, Ferretti M, et al. Coinherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome. BMC Immunol 2007; 8: 28.

16. Hansford JR, Pal M, Poplawski N, et al. In utero and early postnatal presentation of autoimmune lymphoproliferative syndrome in a family with a novel FAS mutation. Haematologica 2013;98: 38-39.

17. Magerus-Chatinet A, Neven B, Stolzenberg, et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest 2011;121: 106-112.

18. Arico M, Boggio E, Cetica V, et al. Variations of the UNC13D gene in patients with autoimmune lymphoproliferative syndrome. PLoS One 2013; 8: 68045.

19. Rensing-Ehl A, Warnatz K, Fuchs S, et al. Clinical and immunological overlap between autoimmune lymphoproliferative syndrome and common variable immunodeficiency. Clin Immunol 2010; 137:357-365.

20. Ameratunga R, Brewerton M, Slade C, et al. Comparison of diagnostic criteria for common variable immunodeficiency disorder. Front Immunol 2014; 5: 415.

21. Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 2005;105:2443-2448.

22. Seif AE, Manno CS, Sheen C, et al. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood 2010;115: 2142-2145.